Our Opinion

Chiasma, Inc. is on the Cruelty Free Investing use of animals list because they conduct Pre-clinical studies of their drugs on animals to assess a product’s safety profile.

Supporting Evidence:

Chiasma Provides Updates on Scientific Achievements

“We have recently demonstrated that administration of protein drugs formulated with the TPE technology to rats and pigs resulted in blood levels comparable to those achieved after injection of these drugs. The similarity in outcomes in both rodents and large animals as well as the capability to use the technology with drug molecules of varying sizes and characteristics is encouraging and paves the way for our first trials in humans.”

Company Description

Chiasma, Inc. operates as a pharmaceutical company that develops and commercializes oral forms of therapies that are available by injection. Its lead product candidate, oral octreotide, is a formulation of octreotide designed to achieve biochemical disease control, that is, reduced levels of GH and IGF-1, and improved symptom control while addressing the pain and treatment burdens commonly experienced with current injectable therapies. It transforms injecatable drugs into oral medications. The company was founded by Shmuel A. Ben-Sasson and Guy Yachin on April 12, 2001 and is headquartered in Waltham, MA. [Source: MarketWatch]

Company Website: http://www.chiasmapharma.com